{"nctId":"NCT01368497","briefTitle":"Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection","startDateStruct":{"date":"2012-09"},"conditions":["Hepatitis B"],"count":60,"armGroups":[{"label":"Entecavir and peginterferon","type":"EXPERIMENTAL","interventionNames":["Drug: Entecavir and peginterferon"]}],"interventions":[{"name":"Entecavir and peginterferon","otherNames":["PEGASYS, peginterferon alfa 2a, Baraclude"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Enrolled in \\& completed the baseline evaluation in NCT01263600 OR completed necessary components of NCT01263600 baseline evaluation by the end of the baseline visit.\n* 3 to \\<18 years at time of randomization (day 0).\n* Documented chronic Hepatitis B virus (HBV) infection as evidenced by detection of hepatitis B surface antigen (HBsAg) in serum for ≥ 24 weeks prior to baseline OR positive HBsAg and negative anti-Hepatitis B core (HBc) immunoglobulin (IgM) within 24 weeks of baseline visit.\n* Presence of hepatitis B e-antigen (HBeAg) in serum at the last screening visit within 6 weeks of baseline visit.\n* Serum HBV DNA level \\>10\\^7 IU/mL on at least 2 occasions at least 12 weeks apart during the 52 weeks before baseline visit. The HBV DNA levels must be within 6 weeks of baseline visit.\n* ALT ≤60 U/l in males or ≤40 U/l in females, measured on at least 2 occasions, at screening (within 6 weeks prior to baseline visit) \\& at least 12 weeks prior to the screening visit \\& within the 52 weeks prior to baseline visit.\n* Compensated liver disease, with normal total bilirubin (except if Gilbert's syndrome), direct bilirubin ≤0.5 mg/dL, International Normalized Ratio (INR) ≤1.5, and serum albumin ≥3.5 g/dL.\n* Creatinine clearance 90 ml/min.\n* Absence of hepatocellular carcinoma on liver ultrasound in the past 48 weeks.\n\nExclusion criteria:\n\n* Presence of infection with Hepatitis C virus (HCV)-RNA or anti-HCV, anti-Hepatitis D virus (HDV), or HIV at screening.\n* Presence of another cause of liver disease or hepatocellular cancer (HCC) (serum alpha-fetoprotein \\>50ng /ml).\n* Evidence of decompensated liver disease (Childs B-C).\n* History or other evidence of a medical condition associated with chronic liver disease (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures).\n* Females who are pregnant or breastfeeding.\n* Adolescent females unwilling or unable to use an acceptable method of contraception if sexually active during the treatment period.\n* Children currently breastfeeding while their mother is taking lamivudine, or those who were exposed to lamivudine for ≥24 weeks via maternal lamivudine treatment during pregnancy and/or while breastfeeding.\n* Previous liver or other organ transplantation including engrafted bone marrow transplant.\n* Hematological abnormalities during the screening period that contraindicate full dosing with study drugs, e.g absolute neutrophil count \\< 1.5 x 10\\^9 cells/L or platelet count \\< 120 x 10\\^9 cells/L.\n* Known allergy to study drugs; peginterferon alfa-2a or entecavir.\n* Treatment with systemic acyclovir or famciclovir within the previous 6 months.\n* Need for ongoing use of any antivirals with activity against HBV during the course of the study or history of receiving treatment for HBV.\n* Any use of illegal drugs OR use of alcoholic beverages which in the opinion of a study physician is sufficient to prevent adequate compliance with study procedures or increase the risk of pancreatitis or hepatotoxicity.\n* History of immunologically mediated disease (e.g. inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis).\n* History or other evidence of bleeding from esophageal varices or consistent with decompensated liver disease.\n* History or other evidence of chronic pulmonary disease associated with functional limitation.\n* History of significant cardiovascular diseases.\n* History of a severe seizure disorder or current anticonvulsant use.\n* History or other evidence of severe retinopathy.\n* History of thyroid disease poorly controlled on prescribed medications. Participants with elevated thyroid stimulating hormone concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded.\n* Concomitant use or use during ≤ 6 months prior to the first dose of study drug of anti-neoplastic, immunosuppressive, nephrotoxic or hepatotoxic medication, methadone, theophylline or medications that may affect renal excretion or hepatic metabolism are not permitted.\n* Concomitant use of complementary or alternative medications purported to have antiviral activity.\n* A participant may not be co-enrolled in another clinical trial where an investigational drug is administered.\n* Any other condition or situation that in the opinion of a study physician would make the participant unsuitable for enrollment or could interfere with the participant participating in and completing the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss & Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels ≤1,000 International Units (IU) Per Milliliter (mL)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".033","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events (AEs) Per Person-Year","description":"The number of AEs includes both AEs and Serious Adverse Events (SAEs). The incidence is calculated as the number of AEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Serious Adverse Events (SAEs) Per Person-Year","description":"The incidence is calculated as the number of SAEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".050","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".033","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".033","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".033","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With HBeAg Seroconversion","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".033","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With HBeAg Seroconversion","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".033","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With HBsAg Seroconversion","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".033","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With HBsAg Seroconversion","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".033","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Alanine Aminotransferase (ALT) ≤ 40 Units (U) Per Liter (L) for Males, ≤ 35 U/L for Females","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".350","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With ALT ≤ 40 U/L for Males, ≤ 35 U/L for Females","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".650","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With HBV DNA ≤1000 IU/mL","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".750","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With HBV DNA ≤1000 IU/mL","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".033","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With HBV DNA < 20 IU/mL","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".233","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With HBV DNA < 20 IU/mL","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".033","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion Without Detectable Antiviral Drug-resistance HBV Mutations","description":"HBV drug resistance variant testing was performed at the CDC laboratory. The sequences of the HBV polymerase spanning nucleotide positions 311-1021 were determined by Sanger sequencing. Drug resistance mutations that were tested in this study included L80VI, L82M, T128N, W153Q, F166L, I169T, V173L, L180M, A181TV, T184ACFGILMS, V191T, A194T, A200V, S202ETV, M204IV, V207I, N236T, M250ILV, and G145R.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".733","spread":null}]}]}]},{"type":"SECONDARY","title":"Growth Measures: Z-scores Weight, Height, and Body Mass Index","description":"A child's Z-score is the number of standard deviations that the child is from the average of children of the same sex and age from a reference population. The reference population is provided in the 2000 Centers for Disease Control and Prevention (CDC) growth charts. Positive Z scores mean the growth measure (weight, height, or body mass index) is above the average, negative Z scores mean the growth measure is below the average.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Growth Measures: Z-scores Weight, Height, and Body Mass Index","description":"A child's Z-score is the number of standard deviations that the child is from the average of children of the same sex and age from a reference population. The reference population is provided in the 2000 Centers for Disease Control and Prevention (CDC) growth charts. Positive Z scores mean the growth measure (weight, height, or body mass index) is above the average, negative Z scores mean the growth measure is below the average.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Tanner Stages of Physical Growth","description":"The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Girls selected the picture closest to their self-perceived breast growth from among 5 stages of breast growth and boys did the same for testes, scrotum, and penis growth.\n\nBoys: I-prepubertal; II-enlargement of scrotum and testes; III-enlargement of the penis and further growth of testes; IV- increased size of penis with growth in breadth and development of glans, testes, and scrotum larger, scrotum skin darker; V- adult genitalia.\n\nGirls: I-prepubertal; II-breast bud stage with the elevation of breast and papilla and enlargement of the areola; III-further enlargement of breast and areola, no separation of their contour; IV-areola and papilla form a secondary mound above the level of the breast; V: mature adult stage.\n\nThere is no \"better\" or \"worse\" outcome. They are self-assessed descriptive measures of physical growth.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Tanner Stages of Physical Growth","description":"The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Girls selected the picture closest to their self-perceived breast growth from among 5 stages of breast growth and boys did the same for testes, scrotum, and penis growth.\n\nBoys: I-prepubertal; II-enlargement of scrotum and testes; III-enlargement of the penis and further growth of testes; IV- increased size of penis with growth in breadth and development of glans, testes, and scrotum larger, scrotum skin darker; V- adult genitalia.\n\nGirls: I-prepubertal; II-breast bud stage with the elevation of breast and papilla and enlargement of the areola; III-further enlargement of breast and areola, no separation of their contour; IV-areola and papilla form a secondary mound above the level of the breast; V: mature adult stage.\n\nThere is no \"better\" or \"worse\" outcome. They are self-assessed descriptive measures of physical growth.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Tanner Stages of Pubic Hair Growth","description":"The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Participants selected the picture closest to their self-perceived pubic hair growth.\n\nBoys and girls: I-prepubertal (no pubic hair at all); II-sparse growth of long, slightly pigmented hair, straight or curled, at base of penis or along labia; III: darker, coarser and more curled hair, spreading sparsely over junction of pubes; IV- hair adult in type, but covering smaller area than in adult; V-adult in type and quantity.\n\nThere is no \"better\" or \"worse\" outcome. They are self-assessed descriptive measures of physical growth.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Tanner Stages of Pubic Hair Growth","description":"The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Participants selected the picture closest to their self-perceived pubic hair growth.\n\nBoys and girls: I-prepubertal (no pubic hair at all); II-sparse growth of long, slightly pigmented hair, straight or curled, at base of penis or along labia; III: darker, coarser and more curled hair, spreading sparsely over junction of pubes; IV- hair adult in type, but covering smaller area than in adult; V-adult in type and quantity.\n\nThere is no \"better\" or \"worse\" outcome. They are self-assessed descriptive measures of physical growth.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":60},"commonTop":["Low absolute neutrophil count","ALT or AST elevation","Strep throat","Sinus infection","Neutropenia"]}}}